Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Here we identify inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson's disease.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Gasser, T. Expert Rev. Mol. Med. 11, e22 (2009).
Greggio, E. et al. Neurobiol. Dis. 23, 329–341 (2006).
Smith, W.W. et al. Nat. Neurosci. 9, 1231–1233 (2006).
West, A.B. et al. Hum. Mol. Genet. 16, 223–232 (2007).
Whaley, N.R., Uitti, R.J., Dickson, D.W., Farrer, M.J. & Wszolek, Z.K. J. Neural Transm. Suppl. 70, 221–229 (2006).
Mata, I.F., Wedemeyer, W.J., Farrer, M.J., Taylor, J.P. & Gallo, K.A. Trends Neurosci. 29, 286–293 (2006).
Chin, P.C. et al. J. Neurochem. 90, 595–608 (2004).
Imai, Y. et al. EMBO J. 27, 2432–2443 (2008).
Smith, W.W. et al. Proc. Natl. Acad. Sci. USA 102, 18676–18681 (2005).
Leclerc, S. et al. J. Biol. Chem. 276, 251–260 (2001).
Wang, W. et al. Neuropharmacology 52, 1678–1684 (2007).
Anand, V.S. et al. FEBS J. 276, 466–478 (2009).
Covy, J.P. & Giasson, B.I. Biochem. Biophys. Res. Commun. 378, 473–477 (2009).
Nichols, R.J. et al. Biochem. J. 424, 47–60 (2009).
Reichling, L.J. & Riddle, S.M. Biochem. Biophys. Res. Commun. 384, 255–258 (2009).
We thank C. Burris and L. Lotta for packaging helper virus–free amplicons. C. Cook, K. Kehoe, J. Dunmore and C. Eckman provided technical support for some of the in vivo HSV studies. We also thank G. and K. Caldwell and S. Hamamichi for helpful discussions. This work was supported by grants from the US National Institutes of Health, P50NS38377, R01ES014470 (K.A.M.-Z.), R01-AG023593 (W.J.B.), R00-NS058111 (A.B.W.), NS36420 (H.J.F.) and Army Medical Research and Materiel Command, DAMD17-02-1-0695 (H.J.F.), the Mayo Foundation and the Michael J. Fox Foundation.
T.M.D. is a paid consultant to Merck KGAA. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.
About this article
Cite this article
Lee, B., Shin, JH., VanKampen, J. et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 16, 998–1000 (2010). https://doi.org/10.1038/nm.2199
Impaired dopamine D3 and nicotinic acetylcholine receptor membrane localization in iPSCs-derived dopaminergic neurons from two Parkinson’s disease patients carrying the LRRK2 G2019S mutation
Neurobiology of Aging (2021)
LRRK2 Inhibition Ameliorates Dexamethasone-Induced Glucose Intolerance <i>via</i> Prevents Impairment in GLUT4 Membrane Translocation in Adipocytes
Biological and Pharmaceutical Bulletin (2020)
Distinct Roles for RAB10 and RAB29 in Pathogenic LRRK2-Mediated Endolysosomal Trafficking Alterations
Translational Medicine of Aging (2020)